Incidence of esophagitis, peptic ulcers and small intestinal mucosal lesions induced by loxoprofen, etodolac and celecoxib in healthy volunteers: a prospective randomized comparative trial

Trial Profile

Incidence of esophagitis, peptic ulcers and small intestinal mucosal lesions induced by loxoprofen, etodolac and celecoxib in healthy volunteers: a prospective randomized comparative trial

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jan 2013

At a glance

  • Drugs Celecoxib (Primary) ; Etodolac (Primary) ; Loxoprofen (Primary) ; Famotidine
  • Indications Musculoskeletal disorders; NSAID-induced gastric damage; NSAID-induced gastrointestinal damage; Pain; Rheumatic disorders
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top